Related Experiment Video
Updated: Sep 4, 2025
06:38
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
2.4K
Periorbital edema associated with alpelisib.
Elizabeth A Dao1, Saira J George2, Meghan M Heberton3
1Louisiana State University Health Sciences Center School of Medicine, 2020 Gravier St., New Orleans, LA 70112, USA.
Cancer Treatment and Research Communications
|July 14, 2022
Summary
Alpelisib, a PI3K inhibitor for breast cancer, can cause rare periorbital edema. Early dermatology consultation is key for managing this unique cutaneous side effect.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Alpelisib targets PI3K for HR+/HER2- metastatic breast cancer.
- Common alpelisib side effects include hyperglycemia, rash, and GI upset.
- Morbilliform rash is a typical cutaneous reaction to alpelisib.
Purpose of the Study:
- To report two cases of periorbital edema associated with alpelisib.
- To discuss the clinical presentation, management, and prognosis of this adverse event.
- To emphasize the role of dermatology in managing alpelisib-induced cutaneous reactions.
Main Methods:
- Case report of two patients experiencing periorbital edema.
- Clinical data collection and review.
- Literature review on alpelisib adverse events.
Main Results:
- Two patients developed periorbital edema while on alpelisib therapy.
- The reaction was managed effectively with dermatological intervention.
- Periorbital edema represents a distinct cutaneous adverse event of alpelisib.
Conclusions:
- Periorbital edema is a rare but notable adverse event of alpelisib.
- Prompt dermatological assessment and management are crucial for patients experiencing this reaction.
- Understanding unique alpelisib-induced skin toxicities improves patient care.
